VCP disease associated with Inclusion body myopathy, Paget disease of the bone and frontotemporal dementia is a progressive autosomal dominant disorder caused by mutations in Valosin containing protein gene. To establish genotype-phenotype correlations we analyzed clinical and biochemical markers from a database of 190 members in 27 families harboring ten missense mutations.
INTRODUCTION
Inclusion Body Myopathy associated with Paget's disease of the bone and Frontotemporal Dementia, (IBMPFD, OMIM 167320), first reported by Kimonis et al. (2000) is an autosomal dominant, progressive, and ultimately lethal condition with onset typically in 20s to 40s [1] [2] [3] [4] . Myopathy is the most common feature (90%) and is characterized by progressive weakness and atrophy of skeletal muscles of pelvic and shoulder girdle muscles. Muscle weakness progressively involves the other limb, trunk and respiratory muscles with death from respiratory failure, cardiomyopathy and cardiac failure . EMG in ALS is characterized by neurogenic features which include moderate fibrillation potentials, increased muscle fiber irritability and small amplitude motor potentials. Tucker et al. 12 described the first family with combined lower motor neuron degeneration and skeletal disorganization. This family was subsequently reported to have a VCP mutation by Watts et al. , and this treatment may be potentially useful in preventing PDB in individuals at risk of VCP-associated PDB.
Frontotemporal Dementia (FTD) is a degenerative condition of the frontal and anterior temporal lobes of brain which accounts for a substantial proportion of primary degenerative dementia that occurs earlier than the typical age of 65 years seen in the general population 16 . Disproportionately impaired executive or other frontal lobe functions, associated with changes in behavior and conduct, early in the course of the illness with relative sparing of memory and visuospatial abilities provide strong support for the diagnosis of FTD. 
METHODS

Clinical Evaluation and Diagnosis
Informed consent was obtained from each subject prior to participation. Research studies were approved by the Institutional Review Boards of Southern Illinois School of Medicine, Children's Hospital
Boston and University of California, Irvine. Individuals who participated in clinical, biochemical, and molecular studies were over age 18 years. Subjects were grouped into three categories based upon their mutation status; symptomatic, carriers and non-carrier first degree at risk relatives. Affected individuals were grouped into ten groups based on their VCP mutation R155H, R155C, R155P, R191Q, R159C, R95G, R93C, A232E, L198W and N387H ( Table 1) .
A diagnosis of myopathy was based on the presence of muscular weakness, elevated creatinine kinase in some individuals, and in several patients by EMG and muscle biopsy findings. Clinical findings included an inability to raise their arms and walk up stairs, a lordotic gait from the proximal weakness and in some mild weakness of the hands. Tendon reflexes were absent or reduced. Electrodiagnostic studies, EMG and nerve conduction studies were performed to look for myopathic/neuropathic changes. Sections of unfixed muscle were stained by standard procedures. 
Statistical analysis
Tables of key clinical variables for statistical analysis were generated by cross-tabulation of all the available clinical and laboratory data for members of the 27 families. All the analysis was performed using SPSS® statistical package (v.15.0). Survival time was analyzed using the Kaplan-Meier survival method.
Comparisons were made between normal controls, presymptomatic and symptomatic patients. For each marker, the least squares means were calculated for each of the 3 diagnosis groups (adjusted for age and gender). Possible interactions of age and gender were analyzed. A p-value of ≤0.05 was considered significant.
Molecular Studies
Mutation analysis of the VCP gene (NM_007126) was carried out as previously described 7 .
Sequences longer than 1000 bp were divided into multiple, overlapping segments for amplification. PCR products were gel purified using the Gel Extraction Kit (Qiagen, Valencia, CA), and sequenced with an ABI 377 sequencer, using a dRhodamine terminator cycle sequencing kit (Applied BioSystems Inc., Foster City, CA).
RESULTS
The clinical data from the 27 families representing 190 individuals carrying VCP mutations (94 males, 96 females) were analyzed. Of these individuals, 145 (73 males, 72 females) were clinically symptomatic, and 45 (21males, 24 females) were presymptomatic carriers.
Myopathy
Of 
Muscle biopsies
Histopathology of muscle biopsies revealed myopathic changes including variation in muscle fiber size and mildly increased endomysial connective tissue in some regions of the specimen. Rimmed vacuoles were present in 35% of 105 muscle biopsies studied. Nuclear and cytoplasmic inclusions were immunopositive for ubiquitin and TAR DNA-binding protein 43 (TDP-43). 
Paget's disease of bone (PDB)
PDB
Genotype / Phenotype Studies
To investigate the phenotypic variations of the different mutations, the families were divided into ten groups depending on the VCP mutation identified in the gene ( Table 1) . The mean age of onset for IBM, PDB, FTD and biological markers for affected individuals within each mutation group (Table 4) were analyzed, however, some of the groups were very small and therefore, statistically significant differences could not be identified except for Group 2 with mutation R155C associated with a significantly earlier onset for symptoms of myopathy and PDB when compared with group 1 with mutation R155H (p=0.033
and 0.023 respectively). This group showed significantly reduced mean survival (p=0.029) when compared to other groups. There were no significant differences in the other markers for muscle and bone turnover like ALP, PYD, DPD or DPD/PYD between the groups. The clinical and biochemical markers were also analyzed by grouping mutations in different domains (CDC ubiquitin binding, Linker L1
and ATPase domains), but statistically significant differences were not appreciated.
Survival with different mutation groups was also analyzed. Group 2 with mutation R155C had a reduced mean survival of 58.518±2.78 years compared to group 1 with mutation R155H with a mean survival of 63.195±2.62 years (p=0.029) (Figure 1) . The majority of the groups were too small for intergroup analysis.
Amyotrophic lateral sclerosis (ALS)
ALS was reported in at least 13 individuals in these 27 families; 10 individuals with mutation R155H (three from family 4, three from family 7 and two from family 3), one with mutation R155C (family 2), one with mutation R95G (family 9) and one with mutation A232E (family 6). This accounts for 8.9% of individuals affected with VCP disease, this being significantly higher than would be expected 'by chance'
given the incidence rate of ALS in general population of 2 per 100,000 per year. Interestingly in family 6 with mutation A232E, previously reported as having a more severe phenotype with earlier age of onset and more aggressive disease 7 , one of the three individuals was diagnosed with ALS.
Parkinson's disease
The proband of family 24 with an R159C mutation had classic Parkinson's disease (PD) 24 , and recently his sister has also been diagnosed with PD. Several individuals in family 16 were diagnosed with PD, however these individuals are deceased and PD could not be conclusively confirmed in them.
Interestingly, none of the 13 individuals in family 24 had PDB suggesting that mutation R159C may be protective for PDB. Further studies in larger groups of patients with this mutation are necessary to evaluate these findings.
Alzheimer's disease
Some individuals were diagnosed with Alzheimer's disease, this diagnosis having been confirmed by neuropathology in one patient from family 3 with mutation R155H and two APOE4 alleles, which has been previously shown to increase the risk for FTD, but not PDB or IBM 
DISCUSSION
Since the first family reported by Kimonis et al. Phenotypic heterogeneity, both within and between different families containing the same VCP mutation of disease severity, distribution of weakness, presence or absence of Paget's disease or cognitive impairment makes genotype-phenotype correlations difficult, nevertheless we found that the R155C mutation was more severe than R155H. We previously reported a severe phenotype in a small family with A232E mutation 11 , one member of which developed ALS. In a recent study, Niwa et al. (2012) analyzed the ATPase activities of ten major IBMPFD mutants and found that all have increased activity over the wild type, with the A232E and R155C mutations having the highest activities 27 . The molecular mechanism for these observed differences may be related to its binding with its cofactors 28 .
Review of the survival curves indicated that the average life span after diagnosis of myopathy and
Paget is 18 and 19 years respectively. However, dementia heralded rapid acceleration of the progression of the disease with an average life span of 6 years. As the muscle weakness ultimately involves respiratory muscles, death is typically from respiratory failure or cardiac failure. Sex differences were observed in the incidence of FTD but not in the incidence of myopathy and Paget's disease. Although, none of the mutations had a significant effect on the age of onset for FTD, there was an increase in the incidence of FTD among females (F: M showed a 2:1 ratio). Alzheimer's Disease (LOAD) risk factor on chromosome 9 and identified a novel R92H mutation
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. One individual with mutation R155H and two apolipoprotein E (APOE) 4 alleles was identified in our study group who was diagnosed with true Alzheimer's disease (AD).
We also reviewed the clinical features in patients and families with IBMPFD reported from several parts of the world ( 
